Mal-Val-Ala-PAB-N(SO2Me)-Exatecan

Name: Mal-Val-Ala-PAB-N(SO2Me)-Exatecan
Brand: MedChemExpress
SKU: HY-159072
Rating: 4.5 (1 reviews)

Cat. No.: HY-159072: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, K_D=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer.

For research use only. We do not sell to patients.

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan Chemical Structure

CAS No. : 2575682-08-3

Size	Price	Stock	Quantity
1 mg	USD 750	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 1750	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 2800	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms

Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1141.22

Formula

C₅₆H₆₅FN₈O₁₅S

CAS No.

2575682-08-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C=CC1=O)N1CCCCCC(N[C@@H](C(C)C)C(N[C@@H](C)C(NC(C=C2)=CC=C2COC(N(CCS(C)(=O)=O)COCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (87.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8763 mL	4.3813 mL	8.7626 mL
5 mM	0.1753 mL	0.8763 mL	1.7525 mL
10 mM	0.0876 mL	0.4381 mL	0.8763 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Guo Q, et al., FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28. [Content Brief]

[2]. Liu N, et al., Preparation method of linker drug conjugate and intermediate thereof. CN116178386.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.8763 mL	4.3813 mL	8.7626 mL	21.9064 mL
	5 mM	0.1753 mL	0.8763 mL	1.7525 mL	4.3813 mL
	10 mM	0.0876 mL	0.4381 mL	0.8763 mL	2.1906 mL
	15 mM	0.0584 mL	0.2921 mL	0.5842 mL	1.4604 mL
	20 mM	0.0438 mL	0.2191 mL	0.4381 mL	1.0953 mL
	25 mM	0.0351 mL	0.1753 mL	0.3505 mL	0.8763 mL
	30 mM	0.0292 mL	0.1460 mL	0.2921 mL	0.7302 mL
	40 mM	0.0219 mL	0.1095 mL	0.2191 mL	0.5477 mL
	50 mM	0.0175 mL	0.0876 mL	0.1753 mL	0.4381 mL
	60 mM	0.0146 mL	0.0730 mL	0.1460 mL	0.3651 mL
	80 mM	0.0110 mL	0.0548 mL	0.1095 mL	0.2738 mL